文献速递核素与放射性配体治疗放射性药物与辐射防护

AIMN、ITANET与SIE联合立场文件:肽受体放射性核素治疗中神经内分泌肿瘤类癌综合征及类癌危象的识别、预防与管理

AIMN, ITANET, SIE joint position paper for the recognition, prevention and management of NET carcinoid syndrome and crises during peptide receptor radionuclide therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-10-07

该联合立场文件由意大利多学科专家组制定,针对接受[177Lu]Lu-based PRRT的综合征性NET患者,聚焦类癌危象(CC)的管理。专家组基于文献证据及22名意大利NET专家经验,提出关于CC高风险患者识别、预防、PRRT预给药、CC期间管理及辐射防护等推荐。

要点

  • 需识别CC高风险患者并制定预防策略。
  • PRRT预给药应结合行为、营养状态及生长抑素类似物治疗。
  • CC管理包括PRRT期间处理、术后监测及辐射防护。

核心结论

  • 该实用指南总结了意大利NET多学科团队在PRRT相关CS、CHD及CC方面的观点与经验。
  • 推荐应在核医学良好实践背景下应用,不替代国家及国际法律法规。

研究设计与样本

  • 联合意大利多学科专家组基于文献证据及22名NET专家(麻醉、内分泌、消化、核医学、肿瘤、外科)经验制定立场文件。

主要发现

  • 专家组就CC高风险患者识别、CC预防、PRRT预给药、CC期间管理及辐射防护等提出多项推荐。

关键数值与推荐

  • 推荐涉及CC高风险患者识别、预防(含行为营养状态及生长抑素类似物治疗考量)、PRRT预给药实施、CC期间管理(含PRRT后监测及辐射防护)。

临床怎么用

  • 用于支持参与[177Lu]Lu-based PRRT的人员在治疗综合征性NET患者时管理CC。

局限性

  • 推荐需结合核医学良好实践,不替代国家及国际法律或监管规定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Carcinoid syndrome (CS) is the most frequent neuroendocrine tumor (NET)-related syndrome with variable presentations related to hormonal discharge and long-term complications, such as carcinoid heart disease (CHD). Carcinoid crisis (CC) is an acute and serious CS complication, due to a massive release of vasoactive hormones and biologically active substances, which may occur during stressogenic procedures such as peptide receptor radionuclide therapy (PRRT). CC is an emergency and life-threatening condition that needs to be prevented, promptly recognized, and managed. The purpose of this joint Italian multidisciplinary position paper is to support the involved personnel in delivering [177Lu]Lu-based PRRT to syndromic NET patients, focusing on CC management. METHODS: The literature evidence regarding CS, CHD, and CC during/after PRRT and the knowledge of 22 Italian NET experts in Anesthesiology, Endocrinology, Gastroenterology, Nuclear Medicine, Oncology, and Surgery involved in PRRT were the basis for the present document. RESULTS: The expert panel expressed several recommendations regarding: 1) CC high-risk patients identification; 2) CC prevention, including considerations of the behavioral and nutritional status, and somatostatin analogue therapy; 3) how to implement PRRT premedication in CC high-risk patients; 4) how to manage CC during PRRT, including post-PRRT monitoring, and radiation protection considerations. CONCLUSION: This practical guide summarizes the views and experience in CS, CHD, and CC in relation to PRRT of a joint NET-dedicated Italian multidisciplinary team. These recommendations should be taken into the context of Nuclear Medicine good practice and do not substitute any national and International legal or regulatory provisions.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Laudicella R, Faggiano A, Pirro V, et al. AIMN, ITANET, SIE joint position paper for the recognition, prevention and management of NET carcinoid syndrome and crises during peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2025. PMID: 41055768. doi:10.1007/s00259-025-07596-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。